1-3 of 3
David Shum, M.S.
Close
Sort by
Journal Articles

Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Customize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML).

Kristen M O'Dwyer, M.D., David Shum, M.S., Mark Heaney, MD, PhD, Renier J. Brentjens, MD, PhD, Peter Maslak, MD, Joseph G Jurcic, MD, Hakim Djaballah, Ph.D., Mark G. Frattini, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2657.
https://doi.org/10.1182/blood.V114.22.2657.2657
Published: 2009
Journal Articles

Discovery and Validation of a Novel Class of Small Molecule Inhibitors of the CDC7 Kinase: Modulation of Tumor Cell Growth in Vitro and In Vivo .

Mark G. Frattini, MD, PhD, David Shum, M.S., Kristen M O'Dwyer, M.D., Renier J. Brentjens, MD, PhD, Peter Maslak, MD, Mark Heaney, MD, PhD, Joseph G Jurcic, MD, Hakim Djaballah, Ph.D., Thomas J Kelly, M.D., Ph.D.
Journal: Blood
Blood (2009) 114 (22): 3771.
https://doi.org/10.1182/blood.V114.22.3771.3771
Published: 2009
Journal Articles

Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo

Mark G. Frattini, MD, PhD, David Shum, M.S., Kristen M O’Dwyer, M.D., Renier J. Brentjens, MD, PhD, Ray Yeh, Ph.D., Peter Maslak, MD, Mark Lawrence Heaney, MD, PhD, Joseph Jurcic, MD, Hakim Djaballah, Ph.D., Thomas J Kelly, M.D., Ph.D.
Journal: Blood
Blood (2008) 112 (11): 2668.
https://doi.org/10.1182/blood.V112.11.2668.2668
Published: 2008